Heat Biologics Inc. (NASDAQ: HTBX) Starts Presentation at the 2017 Marcum Microcap Conference
Heat Biologics (NASDAQ: HTBX) is an immuno-oncology company developing novel therapies designed to activate a patient's immune system against cancer. Heat has generated highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT. These technologies, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ "killer" T cells; reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients' immune response. Heat is conducting a Phase 2 trial with HS-110 in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell…







